NCT01686529

Brief Summary

The aim of this study was to investigate the efficacy and safety of subconjunctival bevacizumab application as an adjuvant therapy for primary pterygium.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
49

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Mar 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2012

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

September 11, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 18, 2012

Completed
Last Updated

December 6, 2013

Status Verified

December 1, 2013

Enrollment Period

11 months

First QC Date

September 11, 2012

Last Update Submit

December 5, 2013

Conditions

Keywords

Pterygiumbevacizumabautoconjunctival graft

Outcome Measures

Primary Outcomes (1)

  • Pterygium recurrence

    The pterygium recurrence is evaluated at one year postoperative

    One point.

Secondary Outcomes (1)

  • Conjunctival ischemia

    Ischemia is measured at 24 h, 1 week, 15 days, six months and one year postoperative

Study Arms (3)

One subconjunctival injection

EXPERIMENTAL

Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery

Procedure: Autoconjunctival graftingDrug: Subconjuntival bevacizumab injection

Two subconjuctival injections

EXPERIMENTAL

Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery

Procedure: Autoconjunctival graftingDrug: Subconjuntival bevacizumab injection

Conventional treatment

ACTIVE COMPARATOR

Autoconjunctival grafting without subconjuntival bevacizumab injection

Procedure: Autoconjunctival grafting

Interventions

The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.

Conventional treatmentOne subconjunctival injectionTwo subconjuctival injections

The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.

Also known as: Avastin
One subconjunctival injectionTwo subconjuctival injections

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with primary pterygium

You may not qualify if:

  • Patients with diabetes mellitus
  • collagenopathies,
  • previous ocular surgeries,
  • pregnant or lactating patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto de Oftalmología

Mexico City, Mexico City, 06800, Mexico

Location

Related Publications (1)

  • Nava-Castaneda A, Olvera-Morales O, Ramos-Castellon C, Garnica-Hayashi L, Garfias Y. Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up. Clin Exp Ophthalmol. 2014 Apr;42(3):235-41. doi: 10.1111/ceo.12140. Epub 2013 Jul 5.

Related Links

MeSH Terms

Conditions

Pterygium

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Conjunctival DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Officials

  • Yonathan Garfias, MD, PhD

    Instituto de Oftalmología

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2012

First Posted

September 18, 2012

Study Start

March 1, 2010

Primary Completion

February 1, 2011

Study Completion

February 1, 2012

Last Updated

December 6, 2013

Record last verified: 2013-12

Locations